Skip to main content
. Author manuscript; available in PMC: 2013 Jun 17.
Published in final edited form as: J Am Coll Surg. 2009 May;208(5):906–916. doi: 10.1016/j.jamcollsurg.2009.01.035

Figure 2.

Figure 2

Pathologic T stage for neoadjuvant aromatase inhibitor treated patients (n = 96) separated by operative outcomes. Ninety-six patients had operations after neoadjuvant endocrine therapy alone, of whom 48 had breast-conserving surgery (BCS) (dark bars) and 48 had mastectomy (light bars). Pathologic stage was determined by American Joint Committee on Cancer criteria.